🟢 Immunitybio is trading 4.3% up — no confirmed catalyst

Immunitybio is trading at $8.14 (+4.29%), with no confirmed catalyst for the move.

• The latest listed company release was an October 21 trial database-lock update; results are expected in November.
• An October 27 report linked overnight gains to Jim Cramer calling ImmunityBio a “very good spec” and discussing biotech takeovers, but did not establish the cause of the current intraday move.
• The supplied market snapshot is mixed and does not clearly explain the gain.